⌕
Denali Therapeutics · DNLI · Nasdaq
Tenet 54 · Mixed
Compare
$18.08−3.52%At closeTenet 54 · Mixed
$18.08−0.66 (−3.52%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Denali Therapeutics (DNLI) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is DNLI's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Defense WorldNov 15, 2026 · 11:19 ET
Denali Therapeutics Inc. $DNLI Position Boosted by Fisher Asset Management LLC

Fisher Asset Management LLC boosted its position in Denali Therapeutics Inc. (NASDAQ: DNLI) by 1.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institu…

DNLI −3.5% todayRead at source ↗
● Seeking AlphaNov 13, 2026 · 20:08 ET
Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 Transcript…

DNLI −3.5% todayRead at source ↗
● Seeking AlphaNov 13, 2026 · 08:27 ET
Denali: Commercial Biotech, Scaled The Brain's Wall Once, Second Summit In Sight (Initiating Buy)

I initiate Denali Therapeutics at Buy, as the Avlayah launch has validated the TransportVehicle platform and turned DNLI into a commercial-stage story. Q3 Avlayah sales of $17.8M crushed the $10-12M guide, and Q4 guidanc…

DNLI −3.5% todayRead at source ↗
● MarketBeatNov 13, 2026 · 08:17 ET
Denali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones Near

Denali Therapeutics NASDAQ: DNLI is targeting all eligible U.S. patients for its Hunter disease treatment AVLAYAH, while preparing data updates across a pipeline that includes treatments for Sanfilippo syndrome, Pompe di…

DNLI −3.5% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 15:06 ET
DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?

Denali Therapeutics gains 7.8% as Avlayah sales surge nearly fivefold, reimbursement coverage expands and multiple pipeline catalysts approach.…

DNLI −3.5% todayRead at source ↗
● Seeking AlphaNov 3, 2026 · 21:45 ET
Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript

Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript…

DNLI −3.5% todayRead at source ↗
● MarketBeatNov 3, 2026 · 19:15 ET
Denali Therapeutics Q3 Earnings Call Highlights

Denali Therapeutics NASDAQ: DNLI reported third-quarter 2026 net product revenue of $17.8 million from AVLAYAH, its treatment for Hunter syndrome, as expanding payer coverage and transitions of clinical-trial participant…

DNLI −3.5% todayRead at source ↗
● Zacks Investment ResearchNov 3, 2026 · 18:51 ET
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates

Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $0.74 per share a year ago.…

DNLI −3.5% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarter Continued growth expectations drive Q4 2026 net product revenue guidance of $30.0 million to $32.0 …

DNLI −3.5% todayRead at source ↗
● GlobeNewsWireOct 30, 2026 · 09:30 ETCOMPANY'S OWN WORDS
Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that AVLAYAH® (tividenofusp alfa-eknm) has been recognized as the “Best Biotechnology Product” of 202…

DNLI −3.5% todayRead at source ↗
● GlobeNewsWireOct 22, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the third quarter ended September 3…

DNLI −3.5% todayRead at source ↗
● Defense WorldSep 17, 2026 · 04:42 ET
Engineers Gate Manager LP Boosts Stock Position in Denali Therapeutics Inc. $DNLI

Engineers Gate Manager LP lifted its position in Denali Therapeutics Inc. (NASDAQ: DNLI) by 256.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission…

DNLI −3.5% todayRead at source ↗
● Defense WorldSep 17, 2026 · 04:11 ET
WINTON GROUP Ltd Decreases Position in Denali Therapeutics Inc. $DNLI

WINTON GROUP Ltd decreased its position in Denali Therapeutics Inc. (NASDAQ: DNLI) by 80.2% during a recent quarter, according to its most recent disclosure with the SEC. The fund owned 14,100 shares of the company's sto…

DNLI −3.5% todayRead at source ↗
● Defense WorldSep 16, 2026 · 01:29 ET
Critical Survey: Denali Therapeutics (NASDAQ:DNLI) vs. Altimmune (NASDAQ:ALT)

Altimmune (NASDAQ: ALT - Get Free Report) and Denali Therapeutics (NASDAQ: DNLI - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strengt…

DNLI −3.5% todayRead at source ↗
● Seeking AlphaSep 14, 2026 · 19:41 ET
Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

DNLI −3.5% todayRead at source ↗
● Defense WorldAug 26, 2026 · 04:13 ET
BlackRock Inc. Takes Position in Denali Therapeutics Inc. $DNLI

BlackRock Inc. bought a new stake in Denali Therapeutics Inc. (NASDAQ: DNLI) in a recent quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 14,026,…

DNLI −3.5% todayRead at source ↗
● Zacks Investment ResearchAug 20, 2026 · 13:21 ET
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?

Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.…

DNLI −3.5% todayRead at source ↗
● Seeking AlphaAug 19, 2026 · 08:01 ET
Denali Therapeutics: Bullish On Avlayah And Their Prospects

AVLAYAH's approval has helped validate Denali Therapeutics' TransportVehicle platform. They're now moving into their commercial stage as a business. Early payer coverage and Q3 guidance support a credible launch ramp. Ho…

DNLI −3.5% todayRead at source ↗
● Defense WorldAug 19, 2026 · 04:01 ET
Head to Head Comparison: Denali Therapeutics (NASDAQ:DNLI) versus Humacyte (NASDAQ:HUMA)

Denali Therapeutics (NASDAQ: DNLI - Get Free Report) and Humacyte (NASDAQ: HUMA - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength …

DNLI −3.5% todayRead at source ↗

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just DNLI · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.